Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting

Autologous stem cell transplantation (ASCT) is an effective treatment for amyloid light-chain (AL) amyloidosis leading to both deep and durable clonal responses with excellent median overall survival of over five years with those attaining a complete hematologic response and surviving relapse free